Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Heritage Mining's Contact Bay: Two Large Ni-Cu-PGE Mafic-Ultramafic Intrusives (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PMN)

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

GlobeNewswire November 20, 2023

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire November 14, 2023

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

GlobeNewswire September 8, 2023

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

GlobeNewswire August 21, 2023

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire August 14, 2023

New Alzheimer’s drug data shows better treatment is closer than ever

Jon Brown July 18, 2023

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

GlobeNewswire July 17, 2023

ProMIS Announces Completion of Continuance

GlobeNewswire July 14, 2023
View More News ››

Opinion & Analysis (NDAQ:PMN)

Building a Better Covid-19 Antibody Test

Streetwise Reports May 7, 2020

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

Stockhouse Editorial March 28, 2019

Biotech Releases White Paper on Alzheimer's Disease Candidate

Streetwise Reports August 2, 2018

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

Streetwise Reports July 11, 2018

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

Streetwise Reports June 28, 2018
View More Opinion ››

Bullboard Posts (NDAQ:PMN)

RE:Elliot, Ouch to the many haters could be a hate crime !

The real story is not about Promis entering Alzheimer clinical trials that's not going to happen. I said that few years ago , they...
Alex1726 - 11 days ago

RE:RE:Elliot, Ouch to the many haters could be a hate crime !

For sure if you back Roche up 6-7 years ago with Gantenermab Phase 1, but look at the most recent trials not only Prothena and Acumen you...
FarmerBetsy - 12 days ago

RE:Elliot, Ouch to the many haters could be a hate crime !

https://www.roche.com/innovation/process/clinical-trials/about#b74e294d-1765-419e-8b38-96aaa88d62fa What are the different phases...
BottomBroker - 12 days ago

Elliot, Ouch to the many haters could be a hate crime !

An Embarrassment to say moving forward, the IND delayed by what 5-6 months, then delay another 6 months and start testing 8 healthy...
FarmerBetsy - 12 days ago

Let's goooooooooooo!

To the many haters who said this day would never come, it's here. To the many haters who say this company is worthless, __ _____ ___...
Gbathat - 12 days ago

Worst performing Biotech

But we pay the highest salaries for the worst people. This is a 2 cent stock .
goldtech - 13 days ago
View more Bullboard ››

Vertex Resource Group Ltd.

Vertex Resource Group Ltd.

Vertex Resource Group Ltd. is a Canada-based provider of environmental and industrial services. It provides environmental ...
View More »